›› 2018, Vol. 38 ›› Issue (9): 1104-.doi: 10.3969/j.issn.1674-8115.2018.09.017

• Review • Previous Articles     Next Articles

Advances of anti-inflammation therapy targeting ApoB-100 against atherosclerosis

GUO Xiao-yu, XUE Yu-chen, HE Bin, XUE Xiao-mei, HONG Ting, YOU Sha-sha   

  1. Department of Anesthesiology and SICU, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2018-09-28 Published:2018-10-15
  • Supported by:
    National Natural Science Foundation of China, 81470390; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Support, 20152218; Clinical Research Plan of Shanghai Hospital Development Center, 16CR3006A; Program of Science and Technology Commission of Shanghai Municipality, 17411954700

Abstract: Atherosclerosis is an inflammatory disease of arterial wall causedmany factors, which is the main pathological basis of many cardiovascular diseases. Currently, "inflammatory response" theory is widely accepted as pathogenesis of atherosclerosis. Abnormal increase of apolipoprotein ApoB-100, a composition of low density lipoprotein (LDL), which causes pathological inflammation, is a major factor leading to atherosclerosis. Therefore, inhibition of ApoB-100 induced pathological inflammatory responseimmunotherapy is expected to delay the development of atherosclerosis. This review focused on the recent advances of ApoB-100 vaccine and other ApoB-100 inhibitors against atherosclerosis.

Key words: ApoB-100, atherosclerosis (AS), immunization, vaccine, inhibitor

CLC Number: